Navigation Links
New Study Shows ENJUVIA® Significantly Reduced 'Sleep Time' Awakenings Caused by Hot Flashes in Postmenopausal Women
Date:5/18/2010

SAN FRANCISCO, May 18 /PRNewswire/ -- Teva Women's Health, Inc. today presented data that demonstrated patients treated with a standard or low dose of ENJUVIA® (synthetic conjugated estrogens, B) tablets experienced statistically significant reductions in how often they were awakened at night by hot flashes compared to patients treated with placebo. The data was presented today at the 58th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists in San Francisco.

Hot flashes, caused by menopausal hormone changes, occur in as many as 85 percent of menopausal women, and can be severe enough to negatively impact sleep. The prevalence rate of sleep problems among perimenopausal women and postmenopausal women varies from 31 to 45 percent.

This study evaluated the effectiveness of ENJUVIA (0.3mg and 0.625mg doses) over a 12-week treatment period in reducing the frequency of nighttime sleep awakenings caused by hot flashes in highly symptomatic women. These women were defined as experiencing at least three nighttime awakenings per night at baseline. The study met its primary endpoint of significantly reducing the number of awakenings in both dosing arms with the higher dose achieving a greater mean reduction of 4.56 awakenings per week (p<0.001) than the lower dose (3.55 awakenings per week, p=0.004) relative to placebo. The study did not meet its secondary endpoint of significantly improving individual sleep quality or overall daytime sleepiness as measured by the Stanford Sleepiness Scale Ratings.

"Sleep disruptions due to menopausal symptoms can adversely impact a woman's quality of life," said lead investigator James H. Liu, M.D., Arthur H. Bill Professor and Chair at t
'/>"/>

SOURCE Teva Women's Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ThromboGenics and BioInvent to Receive EUR10 Million Milestone as Partner Roche Begins New Clinical Study with TB-403
2. Whistleblower Lawyers Comment on New England Journal of Medicine Study
3. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
4. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
5. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
6. Spiral Enteroscopy is Three Times Faster than Double-Balloon Enteroscopy in Diagnosing the Small Intestine, New Study Finds
7. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
8. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
9. New Study Shows 84 Percent Reduction in Post-Cesarean Section Infections Through Comprehensive Prevention Strategy
10. Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation
11. Logical Therapeutics Initiates Enrollment in New Gastrointestinal Safety Study in Osteoarthritis Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... YORK , Aug. 20, 2014 ... new market research report is available ... Market for Hospital-Acquired Infection Control (Sterilization, ... http://www.reportlinker.com/p01618925/The-Market-for-Hospital-Acquired-Infection-Control-Sterilization-Disinfection-Testing-and-Treatment.html ... healthcare-associated infections (HAIs), demand has increased ...
(Date:8/20/2014)... Aug. 20, 2014 Reportlinker.com announces that ... its catalogue: The Impact of Healthcare ... http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html The ... is complex legislation that affects virtually every aspect ... are beginning to take effect now. IVD manufacturers ...
(Date:8/20/2014)... , Aug. 20, 2014 ... report is available in its catalogue: ... France, Key Trends and Opportunities to 2018 ... Synopsis The report provides in depth ... French personal accident and health insurance segment, ...
Breaking Medicine Technology:The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 2The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 3The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 4The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 5The Market for Hospital-Acquired Infection Control (Sterilization, Disinfection, Testing and Treatment) 6The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 2Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 3Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 4Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 5Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 6Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 7Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 8Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 9Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 10Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 11Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 12Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 13Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 14Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 15Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 16Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 17Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 18Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 19Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 20Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 21Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 22Personal Accident and Health Insurance in France, Key Trends and Opportunities to 2018 23
... - Biovest,International, Inc. (OTCBB: BVTI), a majority owned ... 2007 blinded interim data from the start of ... for Non-Hodgkin's,lymphoma (NHL) from September 2000 through June ... data that has been made available,to the Company ...
... at the 11th International Myeloma Workshop -, NORTH ... -- The International Myeloma Foundation (IMF) --,supporting research ... families, researchers and physicians -- today,said that updated ... Greece demonstrate improved survival for a wide,range of ...
Cached Medicine Technology:Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 2Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 3Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 4Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable,Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical,Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkin's Lymphoma 5The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 2The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 3The International Myeloma Foundation Says Data Reported at a Global,Medical Meeting in Greece Demonstrates Improved Survival for a Wide,Range of Myeloma Patients 4
(Date:8/20/2014)... In its latest blog post, A Forever ... gets clients off to a great start and gives them ... highlighting an important and possibly life-changing – perhaps even life-saving ... to understand the insidious nature of drug abuse: it doesn’t ... abuse targets a certain socioeconomic group, such as inner-city youth ...
(Date:8/20/2014)... CA (PRWEB) August 20, 2014 The ... that Munira Lokhandwala, DDS, FAGD of Starbrite Dental in ... the AGD 2014 Annual Meeting & Exhibits, which took ... Award is presented to dentists who seek to provide ... profession. To earn this prestigious honor, Dr. Lokhandwala completed ...
(Date:8/20/2014)... straight women are much more likely to seek treatment ... new study finds. Researchers examined data gathered from ... took part in polls in 2002 and 2006-2010, conducted ... study. In the first poll, 13 percent of ... This ranged from getting advice from doctors to more ...
(Date:8/20/2014)... August 20, 2014 Transrectal ultrasound guided biopsy is ... reports have suggested that the number of risks associated ... population-based study, Swedish researchers found that six percent of ... tract infection within 30 days after having a prostate ... five years, reports The Journal of Urology . ...
(Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
Breaking Medicine News(10 mins):Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 2Health News:New A Forever Recovery Blog Post Reminds People that Drug Abuse Doesn’t Discriminate 3Health News:Fremont Dentist Receives Prestigious AGD Fellowship Award 2Health News:White Women More Likely to Seek Fertility Treatment: Report 2Health News:Severe infections with hospitalization after prostate biopsy rising in Sweden 2Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2
... disparities in longevity still tied to geography, race and income, ... who smoke, have high blood pressure, high blood sugar and ... average of four years, a new study finds. , In ... while women could be shaving 4.1 years off their lives, ...
... ... of the survivors of the earthquake in Haiti. The Grand Canyon University community has donated ... disaster struck on January 12, 2010. , ... Phoenix, AZ (PRWEB) March 23, 2010 -- Grand Canyon University,s Compassion ...
... ... expanded its continuum of care with a new licensed assisted living center. Under the direction ... a week. The center,s dedicated nurses and aides provide care and support to residents, helping ... ...
... a Preferred Partner to Genesis Rehab Services. , ... , , ... ... Being named a Preferred Partner means that Genesis Rehab ...
... BRISBANE, Calif. , March 23 InterMune, Inc. ... Authorization Application (MAA), submitted on March 2 seeking ... (IPF) in adults, was validated by the European Medicines Agency ... the application is complete and that the review process will ...
... ... Software-as-a-Service Model , ... (PRWEB) March 23, 2010 -- Healthmaster®, the worldwide leader in electronic medical record software ... their HealthOffice® Software-as-a-Service (Saas) platform in Online Tech’s SAS-70 certified data centers . ...
Cached Medicine News:Health News:Healthy Living Adds Years to Life 2Health News:Healthy Living Adds Years to Life 3Health News:Healthy Living Adds Years to Life 4Health News:Grand Canyon University (GCU) Creates Special Relief Fund and Raises Money for Haiti Earthquake Survivors 2Health News:Classic Residence by Hyatt at Teaneck Opens Licensed Assisted Living Center 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 2Health News:ReGear Life Sciences Named Preferred Partner to Genesis Rehab Services 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 2Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 3Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 4Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 5Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 6Health News:The European Medicines Agency Completes Validation Stage for InterMune's Marketing Authorization Application for pirfenidone 7Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 2Health News:Online Tech and Healthmaster Sign SaaS Hosting Agreement 3
The Calcitonin ELISA is intended for the quantitative determination of Calcitonin in human serum....
... wavelength (532 nm and 940 nm) laser ... solution. This solid-state laser quickly and effectively ... vulgaris. VariLite offers the clinical versatility to ... deeper, larger vessels in a convenient, affordable ...
... PREMIUM SURGICLIP™ clip applier consists of an applier ... 15 or 20 titanium clips. , ,The ... or other tubular structure. As the handles of ... closed around the vessel or structure. As the ...
The LIGACLIP ERCA Endoscopic Rotating Multiple Clip Applier is intended for use on tubular structures or vessels wherever a metal ligating clip is indicated. The tissue being ligated should be consis...
Medicine Products: